Search

Search Constraints

You searched for: Author/Creator Calza, Leonardo

Search Results

21. Prevalence of transmitted drug resistance mutations among newly diagnosed HIV‐1‐infected patients in a large teaching hospital of the Northern Italy. Issue 8 (3rd June 2020)

23. Rosuvastatin decreases serum inflammatory markers and slows atherosclerosis progression rate in treated HIV-infected patients with metabolic syndrome. Issue 2 (1st February 2021)

26. Simplification to dual therapy containing lamivudine and raltegravir or dolutegravir in HIV-infected patients on virologically suppressive antiretroviral therapy. (30th July 2020)

27. Simplification to dual-therapy containing lamivudine and darunavir/ritonavir or atazanavir/ritonavir in HIV-infected patients on virologically suppressive antiretroviral therapy. Issue 5 (4th May 2018)

28. Simplification to High Genetic Barrier 2-Drug Regimens in People Living With HIV Harboring 4-Class Resistance Enrolled in the PRESTIGIO Registry. (1st August 2020)

29. Substitution of nevirapine or raltegravir for protease inhibitor vs. rosuvastatin treatment for the management of dyslipidaemia in HIV-infected patients on stable antiretroviral therapy (Nevrast study). Issue 10 (3rd October 2017)

30. Tenofovir/Emtricitabine/Efavirenz Plus Rosuvastatin Decrease Serum Levels of Inflammatory Markers More Than Antiretroviral Drugs Alone in Antiretroviral Therapy-Naive HIV-Infected Patients. Issue 1 (January 2014)